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Aims: We studied the utility of multimarker risk stratiﬁcation approach to predict cardio-
vascular outcomes in patients with stable coronary artery disease, undergoing elective
percutaneous coronary intervention (PCI).
Methods: We prospectively evaluated 302 consecutive patients with stable coronary artery
disease and normal CPK-MB and cardiac troponin T levels, and who underwent elective PCI
at our institution. The following cardiac biomarkers were measured before and between 12
and 24 h post-procedure: CK-MB, cardiac troponin T, hs-CRP, and NT-ProBNP. Patients were
followed up for a minimum of 6 months.
Results: Post-PCI, CPK-MB levels were elevated but below myocardial infarction (MI) range in
70 patients (23%), and in the MI range in 6 patients (2%). Troponin T levels were detectable
but below the 99th percentile (microleak) in 32 patients (10.6%) and elevated above the 99th
percentile (periprocedural MI) in 104 patients (34.4%). At 9 months' follow-up, 1% died, 2%
had stable angina, 10.3% had non-fatal MI, and 87.7% remained asymptomatic. There was no
signiﬁcant difference in clinical events among groups stratiﬁed by elevation of one bio-
marker or multiple biomarkers.
Conclusion: Single or multiple biomarker strategy in patients with normal baseline biomark-
ers failed to predict major cardiac events after PCI over medium-term follow-up.
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Myocardial damage after percutaneous coronary intervention
(PCI) can result from procedural complications such as distal
embolization, side-branch occlusion, coronary dissection, or
disruption of collateral ﬂow. The incidence of myocardial
damage after PCI, based on signiﬁcant elevation of cardiac
biomarkers, is 1–30%.1 Some of these episodes of periproce-
dural myocardial damage occur silently after uneventful PCI
procedures. Although there is a consensus that troponin is
probably the most relevant biomarker, the prognostic impact
of troponin elevation after PCI is still debated.2–4 The universal
deﬁnition of myocardial infarction (MI) arbitrarily includes
'PCI-related MI' as patients with normal baseline troponin
levels and a rise of troponin three times the 99th percentile of
the upper reference limit (URL).3 Cardiac troponins T (cTnT)
and I (cTnI) are highly sensitive and speciﬁc markers of
myocardial cell injury and necrosis. The prognostic value of
troponins is now well established for patients presenting with
acute coronary syndromes (ACS).4–6 Elevation of troponin
following routine PCI has also been found to be predictive of
both short- and long-term major adverse cardiovascular
events (MACE).7,8 However, there are conﬂicting reports on
the value of cTn in the setting of PCI in stable and unstable
coronary disease.9 Further, while the increasing sensitivity of
cTn assays lowers the number of missed ACS diagnoses, it
presents a diagnostic challenge because the gains in diagnos-
tic sensitivity have inevitably come with a decrease in
speciﬁcity.10
There is growing evidence that combining a biomarker of
hemodynamic stress, such as B-type natriuretic peptide (BNP)
or N-terminal pro-B-type natriuretic peptide (NT-proBNP), and
of inﬂammation, such as high-sensitivity C-reactive protein
(hs-CRP), with a biomarker of necrosis (cardiac troponin)
enhances risk assessment in patients with ACS.11–14 Speciﬁ-
cally, elevated levels of CRP and BNP at presentation identify
patients who are at higher mortality risk, irrespective of
whether or not there is detectable elevation of troponin.15,16
The present study evaluated the clinical impact of a
multimarker risk stratiﬁcation approach on cardiovascular
outcomes in patients with stable coronary artery disease
undergoing elective PCI. This study also evaluated the impact
of micro-cTn leak on long-term outcomes following elective
PCI.
2. Methods
We prospectively evaluated patients with stable coronary
artery disease undergoing elective PCI at G.B. Pant Hospital,
New Delhi, India from June 2010 to May 2011. To ensure that
any post-procedural increase in cardiac markers was exclu-
sively PCI-related, we only included patients with stable
coronary disease or previously stabilized unstable coronary
disease with normal cardiac markers before PCI. Inclusion
criteria were (1) patients with troponin/creatine kinase MB
(CK-MB) values that were assessed pre-PCI and 12–24 h post-
PCI, and where pre-procedure values were within the normal
range, and (2) patients with stable coronary artery disease.Exclusion criteria were (1) patients with cardiac biomarker
elevation (Tn or CK-MB) immediately before PCI, (2) patients
with ACS, and (3) patients with signiﬁcant renal, hepatic, or
any other systemic dysfunction.
Institutional ethical guidelines were followed. All patients
were included after informed consent. All patients were
evaluated after a detailed history, physical examination, and
appropriate investigations. Demographic and clinical charac-
teristics of patients were documented. Blood samples were
collected at baseline and at 8–12 h and 18–24 h after the
procedure, and were analyzed in a core biochemistry laboratory.
All patients were pre-treated with oral aspirin and
clopidogrel 2–6 h prior to the procedure in accordance with
the established protocol. All PCI procedures were performed
using femoral access. Oral aspirin and clopidogrel were
recommended post-PCI for at least 1 year. All patients
undergoing PCI were given 70 IU/kg unfractionated heparin
before PCI, while the use of glycoprotein IIb/IIIa inhibitor and
coronary stent type (bare-metal or drug-eluting stent) was at
the operator's discretion.
Patients with >70% stenosis of only 1 epicardial coronary
artery vessel were classiﬁed as single-vessel disease and those
with >70% stenosis of >1 epicardial coronary artery were
classiﬁed as multivessel disease. Coronary artery lesions were
classiﬁed qualitatively according to modiﬁed American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
classiﬁcation into type A, B, or C; types A and B1 lesions were
categorized as simple, while types B2 and C were categorized
as complex lesions. For each procedure, the duration and
pressure of balloon inﬂation, number, and type of stents were
recorded. Any complications occurring during or within the
ﬁrst 24 h of PCI were also recorded.
Angiographic success was deﬁned as residual coronary
artery stenosis <50% after balloon angioplasty or <20% after
stent implantation, with normal TIMI 3 coronary ﬂow. To rule
out Q-wave MI during the procedure, a 12-lead electrocardio-
gram (ECG) was performed before and at 24 h post-procedure.
Additional ECGs were obtained in patients with post-proce-
dural chest pain.
Pre-PCI blood samples were taken to analyze baseline
myocardial damage marker values. Four cardiac markers,
namely CK-MB, cTnT, hs-CRP, and NT-proBNP, were measured
before and between 12 and 24 h post-procedure. cTnT was
determined using the electro-chemiluminescence analyzer.
cTnT elevation was taken as >3 times laboratory's upper limit
for normal (normal, <0.1 ng/ml, following the universal
deﬁnition of AMI). The lower detectable ranges for serum
NT-proBNP and cTnT were 5 pg/ml and 0.01 ng/ml, respec-
tively. CK-MB elevation was taken as 3 times our laboratory's
upper limit for normal (normal, <25 U/L). Lower detectable
range for CK-MB was 3 U/L.
Plasma and serum samples were collected into aliquots
and stored. cTnT and NT-proBNP levels were determined in
serum samples taken at admission, 12, and 24 h, using the
one-step enzyme immunoassay based on electro-chemolu-
minescence immunoassay by Roche Elecsys, modular Cobas
2010 e 411 (Mannheim, Germany) using commercially
available kits. CK-MB measurements were done by the
principle of immunoinhibition by commercially available
kits by RANDOX Laboratories Ltd., Antrim, United Kingdom
Table 2 – Angiographic and procedural characteristics.
Characteristic Value (n = 302)
Target vessel (%)
Left anterior descending artery 67.5
Right coronary artery 46.5
Left circumﬂex artery 40
Lesion complexity (%)
A 54.9
B 33.8
C 11.8
Multivessel PCI (%) 22
Stent length (mean  SD) (mm) 29.4  14.3
Mean stent diameter (mm) 3.1
Mean number of stents/patient 1.2
Drug eluting stent use 283 (94%)
Longest inﬂation duration (s) 33.4  9
Mean total no. of inﬂations 11.6
PCI, percutaneous coronary intervention.
Fig. 1 – Categories of post-PCI troponin level elevations. PCI,
percutaneous coronary intervention; MI, myocardial
infarction.
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CRP was quantiﬁed by commercially available enzyme linked
immune sorbent assay (ELISA) using commercially available
kit by DCB, Canada (CAN-CRP-4360). Results were compared
with standard curves and the lower detection limit was
0.01 mg/ml.
Patients were divided into 3 groups based on post-PCI
serum cTnT levels: group 1 where cTnT was non-detectable;
group 2 with microleak of cTnT (detectable but below the 99th
percentile), and group 3 with elevated cTnT above the 99th
percentile suggesting myocardial necrosis. Patients were
followed up for at least 6 months by outpatient clinic
attendance, telephonic contact, and review of the medical
notes. Pre-deﬁned endpoints were cardiovascular death,
recurrent ACS, non-elective revascularization, and/or admis-
sion for acute heart failure. When events occurred during
follow-up, we reviewed clinical records to obtain additional
information. MACE was deﬁned as a composite of death from
any cause, MI, and the need for repeat revascularization (new
PCI or coronary revascularization surgery).
Data analysis was performed using IBM SPSS Statistics 20.0
(IBM Corp., Armonk, NY). The frequency of abnormal results
were determined for each marker and compared by the
Fisher's exact test. Continuous variables were expressed as
mean  SD and were compared by the ANOVA test. Results
with a p value <0.05 were considered statistically signiﬁcant.
3. Results
Of the 512 consecutive patients screened for the study from
June 2010 to May 2011, 302 patients were found eligible for this
study. Table 1 shows the baseline demographic characteristics
of the study patients. Table 2 shows the angiographic and
procedural details of the patients.
All patients had normal CPK-MB and cTnT levels pre-PCI as
per protocol. Mean pre-PCI CPK-MB, cTnT, NT-proBNP, and CRP
levels were 18.4 U/L, 0.01 ng/ml, 175.1 pg/ml, and 2.3 mg/ml,
respectively. Mean post-PCI levels of these biomarkers were
30.1 U/L, 0.41 ng/ml, 311.3 pg/ml, and 2.8 mg/ml, respectively.Table 1 – Demographics and baseline patient character-
istics.
Parameter Value (n = 302)
Age (mean  SD) (years) 53.8  10.4
Male 293 (97%)
Hypertension (%) 97 (32%)
Smoking (%) 63 (21%)
Diabetes mellitus (%) 66 (22%)
Recent MI (%) 100 (33%)
Unstable angina (%) 74 (25%)
Chronic stable angina (%) 117 (39%)
Left ventricular ejection fraction
(mean  SD) (%)
50  10.3
Previous PCI (%) 24 (8%)
Prior CABG (%) 3 (1%)
Prior MI (%) 35 (12%)
MI, myocardial infarction; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft surgery.Six (2%) patients had post-PCI CPK-MB levels in the MI range
(>100 U/L). Elevated post-PCI CPK-MB levels but below MI range
(35–100 U/L) were observed in 70 patients (23%). There was no
signiﬁcant difference in age, clinical presentation, vessel
involvement, lesion type, or number of vessels stented between
both groups. At follow-up, there was no signiﬁcant difference in
clinical events between both groups.
Of the 302 patients, post-PCI cTnT level was normal
(<0.01 ng/ml) in 166 patients (55%), detectable but below the
99th percentile (0.01–0.03 ng/ml – microleak) in 32 patients
(10.6%), and elevated cTnT above the 99th percentile (>0.03 ng/
ml, MI) in 104 patients (34.4%) (Fig. 1). Clinical and procedural
characteristics of the 3 groups are summarized in Table 3. B-
type lesion was signiﬁcantly more common in the MI group
(41% vs. 16% in microleak and 29% in normal group; p = 0.007).
Patients in MI group received more balloon inﬂations (mean
12.4 vs. 10.4 in normal group; p = 0.023). There was no
difference in disease burden or other clinical comorbidities
among the three groups. Patients were followed for a median
Table 3 – Clinical characteristics and outcomes on follow-up stratified by troponins categories.
Parameter Normal Microleak Periprocedural MI p value
Age (years) 52.9 52.6 54.6 0.20
Recent MI (%) 34.6 32.3 33.1 0.96
Number of diseased vessels 1.6 1.7 1.6 0.40
Lesion type (A/B/C) 62/29/13 74/16/16 57/41/9 0.17/0.007/0.44
Number of stents 1.1 1.3 1.3 0.052
Total number of inﬂations 10.3 12.4 12.4 0.02
Longest inﬂation (mean) (s) 34 28.1 34 0.003
Follow-up
Angina (%) 2.8 0 3.8 0.62
MI (%) 8.4 3.2 9.4 0.51
Asymptomatic 87.9 93.5 86.9 0.43
MI, myocardial infarction.
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(1.0%) died, 2% had stable angina, 10.3% had non-fatal MI, and
87.7% remained asymptomatic. There was no statistically
signiﬁcant difference in the in the incidence of angina or MI
across the 3 sub-groups.
Next, we stratiﬁed patients into groups based on number of
biomarkers elevated after PCI. Table 4 shows clinical and
procedural characteristics of patients across various groups.
There was no statistically signiﬁcant difference in the incidence
of angina or MI at 9 months follow-up between these groups.
4. Discussion
Large-scale studies, such as by Fuchs et al.17 (n = 1129),
Cavallini et al.18 (n = 3494), and Kini et al.19 (n = 2873), showed
that any increase in post-PCI cTnT has no prognostic
implications during mid- or long-term follow-up, which is
consistent with the ﬁndings of the present study. Nallamothu
et al.20 (n = 1157, with 960 patients in the follow-up) showed
that only very substantial cTnT elevation (>8 times the normal
high levels) was associated with a reduction in long-term
survival. Small-scale studies have shown similar results with
no prognostic implications for post-PCI survival.21–23
All these studies have analyzed the prognostic value of
myocardial damage determined only by measuring post-PCI
cTnT. In this respect, they differ from our study because theyTable 4 – Clinical characteristics and outcomes on follow-up st
Parameter No biomarker Single biomarker Tw
Age (years) 48.3 52.1 
Recent MI (%) 45 34 
Number of diseased vessels 1.5 1.6 
Lesion type (A/B/C) 72/18/9 62/28/15 
Number of stents 1.3 1.2 
Total number of inﬂations 11.9 11.0 
Longest inﬂation (s) 36.8 34.1 
Follow-up
Angina (%) 0 4.7 
MI (%) 9 9.4 
Asymptomatic 91 85.9 
MI, myocardial infarction.included patients with very different degrees of myocardial
damage in the same group. In our study, we combined markers
of myocardial damage, and inﬂammatory and hemodynamic
damage so as to facilitate the deﬁnition of 3 patient groups (no
myocardial damage, minimal myocardial damage (microleak),
and MI) on the basis of the results. Adding CK-MB values
enabled us to distinguish between 2 groups of patients: those
with minimal damage, whose prognosis does not differ from
that of patients with no myocardial damage observed during
the procedure, and those with myonecrosis (major myocardial
damage), whose prospects for survival during follow-up are
worse. Herrmann et al.24 showed that after elective PCI,
elevated troponin T identiﬁed patients at risk of worse long-
term results. Troponin T analysis was conducted quickly at the
patient's bedside. With this test, post-PCI troponin T elevation
was detected in 17.3% of patients, considerably fewer than in
our patients with myocardial damage and in those reported
elsewhere. In a group of 1949 patients, Prasad et al.25 showed
that troponin T elevation, which occurred in 19.6% of patients,
had clear prognostic implications for mortality and incidence
of MI at 2-year follow-up. Moreover, troponin elevation was
shown to be independently related to long-term mortality. In
our study, the short-term (mean follow-up 8 months) results
show non-signiﬁcant correlation with prognostic relation of
post-procedure troponin elevation both in the minimal
myocardial damage (microleak) group as well in myonecrosis
(MI) group.ratified by categories of number of elevated biomarkers.
o biomarkers Three biomarkers Four biomarkers p value
55.1 54.6 52.5 0.12
31 33 35 0.51
1.6 1.6 1.5 0.40
62/33/8 55/40/13 64/35/3 0.96
1.2 1.3 1.3 0.77
11.1 12.6 11.4 0.40
32.9 32.4 35.4 0.35
3.2 2 3.5 0.69
4.3 11.9 7.1 0.60
92.6 84.2 89.3 0.87
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elevation post-PCI (10.6% in microleak and 34.4% in MI range).
Milani et al.9 showed that post-PCI troponin microleak impacts
cardiac prognosis similarly but much less than clear troponin
elevation. Differences in the distribution could be contributed
to the highly sensitive troponin assays used in our study with
lower cut-off values (normal <0.01 ng/ml, microleak 0.01–
0.03 ng/ml, and MI range >0.03 ng/ml), whereas in study by
Milani et al., troponin I was used with a normal reference range
of 0.59 ng/ml. This difference could have contributed to higher
proportion of periprocedural MI and hence a weaker associa-
tion with clinical outcomes. It has been difﬁcult to understand
why modest biomarker elevations after PCI are associated with
an adverse prognosis. It is now clear that individuals at risk for
mortality and/or recurrent AMI are not those who develop de
novo elevations but those with elevations at baseline. It
appears that biomarker elevations mark an adverse anatomic
substrate. Consequently, these patients do worse. Initially, most
studies were done utilizing insensitive assays or high cut-off
values. Patients who develop substantial cTn elevations post-
PCI are those with baseline elevations. Elevations from a normal
baseline are less frequent and, with rare exception, usually
modest. Commonly, minor elevations pre-PCI are accentuated
post-PCI, and if high cut-off values or insensitive assays are
used, it is only post-PCI when they are identiﬁed.
If we factor in the pre-PCI elevation values, the prognostic
importance of post-PCI cTn and/or CK-MB values is totally
obviated.19 However, the baseline value is substantially
prognostic. It is for this reason that recent guidelines indicate
that, in the absence of a normal baseline cTn, one cannot
diagnose post-PCI injury because it is impossible to discern
whether the elevation is related to the initial injury or the PCI.
Consequently, post-PCI injury occurs, and it can be diagnosed
by elevations in cTn if the baseline is normal, but elevations
have little if any prognostic signiﬁcance for cardiac events. If
the baseline is elevated, one should not attempt to make the
diagnosis of post-PCI injury.26
We observed a signiﬁcant rise in overall mean NT-proBNP
levels at 12–24 h post-PCI. Following PCI, 45% of patients had
NT-proBNP >100 pg/ml; nearly 20% of patients had post-PCI
NT-proBNP levels >100 pg/ml despite pre-PCI NT-proBNP
levels <100 pg/ml. Though the prognostic role of natriuretic
peptides following elective PCI and stenting has been
documented, only single pre-procedural levels were evaluated
in these studies.27,28Whether coronary stenting, which results
in shorter procedural ischemic times as compared to plain
balloon angioplasty, is also associated with rise in natriuretic
peptides following PCI has not been well characterized, with
studies reporting conﬂicting results. Though Tateishi et al.29
also reported a rise in BNP at 24 h following plain balloon
angioplasty, our results contrast with previous studies of
temporal changes in BNP levels following coronary stenting.
Cantor et al., in a study of 55 patients undergoing elective PCI,
showed that though BNP levels did not change signiﬁcantly at
6 h post-PCI, there was an insigniﬁcant trend toward higher
values at 18–24 h post-PCI.30 Yildirir et al. demonstrated that in
patients undergoing coronary stenting, PCI did not cause any
signiﬁcant alteration in plasma BNP levels measured either at
1 or 24 h. Those with complex coronary lesions were more
likely to have higher baseline BNP, a difference that persistedafter stenting.31 These differences may be partly explained by
the fact that patients with ACS were excluded in both of these
studies, while our patient population was a relatively
heterogeneous group, with nearly 65% of patients having a
recent ACS. However, despite this, we observed that even
patients with chronic stable angina demonstrated a signiﬁcant
rise in BNP following PCI.
Observational studies have suggested that periprocedural
CRP levels might be a risk indicator for clinical outcomes after
drug-eluting stent implantation. Elevated CRP levels were
independently associated with increased risk of stent throm-
bosis and major clinical events. In the study by Park et al., there
was no association between CRP levels and the need for repeat
revascularization in patients treated with DES.32 These results
were consistent with previous studies reporting the lack of an
association between CRP and repeat revascularization after
bare metal stent treatment.
We hypothesized that the addition of a combination of
biomarkers from different pathophysiological pathways – a
multimarker approach – could add substantial prognostic
information with respect to the risk of MACE post-PCI as
similar to clinical spectrum of spontaneous MI and ACS.
Accordingly, we investigated whether the incorporation of
troponin I, N-terminal pro-brain natriuretic peptide, and hs-
CRP in a model with established risk factors improved the
prediction of MACE post-PCI. Sabatine et al.16 have shown that
it is possible to use a simple multimarker approach combining
each of these markers (BNP, hs-CRP, cardiac troponins),
assigning 1 point for each elevated marker, to improve risk
stratiﬁcation in patients with ACS. With this simple strategy, a
6- to 13-fold gradient of mortality risk may be established
between those without elevation of any marker and those in
whom all 3 markers are elevated.
5. Conclusion
In conclusion, our ﬁndings suggest that simultaneous assess-
ment of troponin, CRP, and BNP in risk stratiﬁcation of patients
undergoing elective PCI does not provide incremental prog-
nostic information. Usage of a simple multimarker strategy, in
which patients are categorized based on the number of
elevated biomarkers, failed to show better risk stratiﬁcation
of patients over a broad range of short- and long-term major
cardiac events. Minor elevation in troponin levels post-PCI
represents myocardial damage and, without meeting the
criteria for necrosis, remains a clinically irrelevant event, not
predicting a subsequent increase in MI or death.
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